ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026

Rhea-AI Summary

ALX Oncology (Nasdaq: ALXO) will report fourth quarter and full year 2025 financial results and provide a business update on Friday, February 27, 2026 before market open.

The company will host a teleconference and live audio webcast at 5:30am PT / 8:30am ET; a replay and corporate presentation will be archived on the investor section of the company website.

News Market Reaction – ALXO

+12.07%

22 alerts

+12.07% Session close to close

+9.5% Peak in 2 hr 22 min

$347.67M Market Cap

1.2x Rel. Volume

In the Feb 19 session, ALXO gained 12.07%, reflecting a significant positive market reaction. Argus tracked a peak move of +9.5% during that session. Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +12.1% in the session following this news. A strong positive reaction aligns with a...

Analysis

The stock surged +12.1% in the session following this news. A strong positive reaction aligns with a stock that has recently responded well to news, including clinical updates and corporate events. Prior announcements in December 2025 and January 2026 produced generally positive price moves, even around financing. However, new highs after earnings dates can be vulnerable if results or guidance disappoint or if prior gains already reflect optimism, so investors have watched how post-event trading compared with these earlier reactions.

Key Figures

Earnings date: February 27, 2026 Conference time PT: 5:30am PT Conference time ET: 8:30am ET

3 metrics

Earnings date February 27, 2026 Scheduled Q4 and full-year 2025 results release before market open

Conference time PT 5:30am PT Start time for earnings teleconference and webcast

Conference time ET 8:30am ET Start time for earnings teleconference and webcast

Historical Context

5 past events · Latest: Jan 30 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 30	Equity offering	Negative	+10.8%	Underwritten share and warrant offering raising about $150M gross proceeds.
Jan 30	Clinical data update	Positive	+10.8%	Exploratory Phase 1b/2 data linking CD47 expression to evorpacept response.
Jan 08	Conference presentation	Neutral	+5.1%	Corporate presentation and fireside chat at J.P. Morgan Healthcare Conference.
Jan 08	Trial advancement	Positive	+5.1%	Progress in ASPEN-09 breast cancer trial and ALX2004 Phase 1 dose escalation.
Dec 07	Positive trial results	Positive	+1.4%	Investigator-sponsored Phase 2 lymphoma data showing high CR and ORR with evorpacept.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news, including positive clinical data and even a dilutive offering, has typically been followed by upward price reactions.

Recent Company History

Over the last few months, ALXO has combined capital raising with steady clinical and corporate progress. A late January 2026 underwritten offering raised about $150 million, yet shares rose over 10% alongside new biomarker data for evorpacept. Earlier in January 2026, the company highlighted advancement of the ASPEN‑09 breast cancer trial and its ALX2004 ADC, and presented at the J.P. Morgan Healthcare Conference, with shares reacting positively. The current earnings-date announcement follows this period of financing, insider buying, and favorable trial updates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced plans to report its fourth quarter and full year 2025 financial results and a business update on Friday, February 27th, 2026 before market open. The company will host a teleconference in conjunction with its financial results press release.

Fourth Quarter and Full Year 2025 Results Webcast Information

Date & Time: Friday, February 27, 2026 at 5:30am PT / 8:30am ET

Webcast Access: https://viavid.webcasts.com/starthere.jsp?ei=1753123&tp_key=d6cfaba210

Participant Listening Options by Phone: To access the conference call, please dial 1-877- 407-0755 or +1-201-389-0913 and ask to be joined into the ALX Oncology Fourth Quarter and Full Year 2025 Financial Results Conference Call.

Another option for instant telephone access to the event is to use the Call me™ link below:
https://callme.viavid.com/viavid/?callme=true&passcode=13755276&h=true&info=company&r=true&B=6

A live audio webcast of the call, along with the ALX Oncology corporate presentation, will be available under "Events & Presentations" in the Investor section of the Company's website, www.alxoncology.com. An archived webcast will be available on the Company's website after the event.

About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action. A Phase 1 dose-escalation trial of ALX2004 is ongoing in patients with EGFR-expressing solid tumors. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.

Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
ewebb@alxoncology.com

Media Contact:
Michele Parisi, SparkPoint Healthcare Communications
mparisi@sparkpointpr.com
(925) 864-5028

FAQ

When will ALX Oncology (ALXO) report Q4 and full year 2025 results?

ALX Oncology will report results on Friday, February 27, 2026 before market open. According to the company, the release is paired with a teleconference and webcast at 5:30am PT / 8:30am ET to discuss the update.

How can investors listen to the ALX Oncology (ALXO) earnings call on February 27, 2026?

Investors can join via a live audio webcast or dial in by phone using provided numbers. According to the company, the webcast link and phone access details are published for the February 27 event.

Where will the ALX Oncology (ALXO) presentation and archived webcast be available?

The corporate presentation and archived webcast will be posted under "Events & Presentations" on the investor website. According to the company, the materials will remain available on www.alxoncology.com after the event.

What time is the ALX Oncology (ALXO) teleconference on February 27, 2026?

The teleconference is scheduled for 5:30am PT / 8:30am ET on February 27, 2026. According to the company, the call accompanies the fourth quarter and full year 2025 financial results release.

Is there an instant phone access option for the ALX Oncology (ALXO) earnings call?

Yes; the company offers a 'Call me' link for instant telephone access to the event. According to the company, attendees can use the provided Call me™ URL and passcode for quick entry.

Will ALX Oncology (ALXO) provide a replay of the February 27, 2026 webcast?

Yes; an archived webcast will be available after the event on the investor website. According to the company, the replay and presentation will be accessible under Events & Presentations on its site.